Clinical trial
Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable…
NCT00003009 · University of Southern California, Other · Terminated
Key facts
| NCT number | NCT00003009 |
|---|---|
| Title | Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer |
| Official title | A Phase I Study of Inhalation of Interleukin-2 (IL-2) in Patients With Metastatic or Unresectable Cancer |
| Lead sponsor | University of Southern California, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Enrollment | 16 |
| Start date | Feb 1, 1996 |
| Primary completion | Aug 1, 2000 |
| Completion | Aug 1, 2000 |
| First posted | Jun 16, 2004 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: